STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells

10/23/2018
STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells
VANCOUVER, BRITISH COLUMBIA, October 23, 2018 – STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339.

mTeSR™1 is an Ancillary Material used in basic and translational research to maintain and expand human pluripotent stem cells (hPSCs) in the undifferentiated state. Used in over 1500 peer-reviewed publications, mTeSR™1 is the most widely published feeder-free cell culture medium, with established protocols for applications ranging from cell line derivation to terminal differentiation. With pre-screened raw materials that ensure batch-to-batch consistency, mTeSR™1 provides robust cultures with homogeneous, undifferentiated phenotypes.

“Advancing our cGMP (Current Good Manufacturing Practices) Ancillary Material suite of products is a top priority for STEMCELL. This further demonstrates to our customers that we are a trusted partner for their bench to bedside translational journey,” says Dr. Allen Eaves, CEO and President of STEMCELL Technologies.

“This is the first of many DMFs to come as we bring more cGMP products to market to support the rapidly growing space of cellular therapies.” says Lynn Csontos, Senior Director, Quality Assurance & Regulatory Affairs.

While there is no regulatory requirement for DMFs, the document provides regulators with confidential, detailed information about the product from inception to commercialization. This allows customers to cross reference the DMF in their own approved IND (Investigational New Drug) or BLA (Biological Licensing Application) applications.

To learn more about how mTeSR™1 and other Ancillary Materials offered by STEMCELL Technologies can help advance your translational journey, contact Lynn Csontos, Senior Director, Quality Assurance & Regulatory Affairs.

Contact
Lynn Csontos, Senior Director, Quality Assurance & Regulatory Affairs
STEMCELL Technologies Inc.
public.relations@stemcell.com

About STEMCELL Technologies STEMCELL Technologies supports life sciences research with more than 2,500 specialized tools and services. We offer high quality cell culture media, cell separation technologies, instruments, accessory products and educational resources that are used by scientists performing stem cell, immunology, cancer, regenerative medicine and cellular therapy research globally.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.